BA lloon Expandable vs. SElf Expanding Transcatheter VaLve for Degenerated BioprosthesIs: Design and Rationale of the BASELINE Trial.

Nuis, Rutger-Jan; van Belle, Eric; Teles, Rui; Blackman, Daniel; Veulemans, Verena; Santos, Ignacio Amat; Pilgrim, Thomas; Tarantini, Giuseppe; Saia, Francesco; Iakovou, Ioannis; Mascherbauer, Julia; Vincent, Flavien; Geleijnse, Marcel; Sathananthan, Janarthanan; Wood, David; Makkar, Raj; Van Mieghem, Nicolas M (2023). BA lloon Expandable vs. SElf Expanding Transcatheter VaLve for Degenerated BioprosthesIs: Design and Rationale of the BASELINE Trial. American Heart Journal, 256, pp. 139-147. Elsevier 10.1016/j.ahj.2022.11.013

[img]
Preview
Text
1-s2.0-S0002870322002952-main.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (996kB) | Preview

BACKGROUND

Surgical aortic valve bioprostheses may degenerate over time and require redo intervention. Transcatheter aortic valve replacement (TAVR) is a less invasive alternative to redo surgery. The BAlloon Expandable vs. SElf Expanding Transcatheter VaLve for Degenerated BioprosthesIs (BASELINE) trial was designed to compare the performance of the balloon-expandable SAPIEN-3 Ultra and the self-expanding EVOLUT PRO+ valve systems in symptomatic patients with a failing surgical bioprosthesis.

METHODS

The BASELINE trial is an investigator-initiated, non-funded, prospective, randomized, open-label, superiority trial enrolling a total of 440 patients in up to 50 sites in 12 countries in Europe and North-America. The primary endpoint is device success at 30-days defined by the Valve Academic Research Consortium-3 Criteria as the composite of technical success, freedom from mortality, freedom for surgery or intervention related to the device or to a major vascular or access-related or cardiac structural complication with an intended performance of the valve (mean gradient <20 mmHg and less than moderate aortic regurgitation). The co-primary endpoint at 1 year is defined as the composite of all-cause death, disabling stroke, rehospitalization for heart failure or valve related problems. Independent Core Laboratories will conduct uniform analyses of echocardiography (pre-, post-, 1-year post-procedure), multi-sliced computed tomography (pre-, and if available post-procedure) and cine-fluoroscopy studies.

CONCLUSIONS

The BASELINE trial is a head-to-head comparative trial investigating the two most used contemporary transcatheter heart valves for the treatment of a failing surgical aortic bioprosthesis. (ClinicalTrials.gov number NCT04843072).

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Pilgrim, Thomas

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0002-8703

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

22 Nov 2022 10:23

Last Modified:

19 Nov 2023 00:25

Publisher DOI:

10.1016/j.ahj.2022.11.013

PubMed ID:

36410441

Uncontrolled Keywords:

Surgical bioprosthetic valve degeneration randomized trial transcatheter aortic valve replacement valve-in-valve

BORIS DOI:

10.48350/175003

URI:

https://boris.unibe.ch/id/eprint/175003

Actions (login required)

Edit item Edit item
Provide Feedback